Leading the creation and development of a transformative biotech startup focused on innovative biologics for autoimmune and inflammatory diseases.Overseeing strategic planning, early R&D, and business development to build a strong pipeline of next-generation therapeutics.Managing early partnerships and intellectual property (IP) strategy to position the company for significant breakthroughs in the Treg and Immune Modulation space.

• Drug Discovery Consultancy providing strategic guidance and advisory services to research biotech in the field of Autoimmunity and IO• Expertise in Biologics, Cellular Therapies• Highly skilled in Treg cell biology/targeting• Specialized in early-stage development, offering comprehensive support from target inception to early preclinical developmentTreg Consultant for Dualyx, Waypoint Bio and other biotech (2023-2024)Chairman of Annual Treg Summits in Boston: •2024: 6th Annual Treg-Directed Therapies Summit: Driving Next-Gen Treg Stimulation for Autoimmunity, Transplantation & Inflammation•2023: 5th Annual Treg Summit: Optimizing Treg Stimulation for Autoimmunity, Transplantation & Inflammation

Dualyx is a biotechnology company committed to advancing groundbreaking Treg-based therapies designed to meet the challenges posed by patients with challenging-to-treat autoimmune diseases. Our innovative pipeline comprises highly promising immune-modulating programs that focus on pivotal control switches for Treg function and biology. This strategic approach positions us to deliver highly appealing Treg therapies.https://www.dualyx.com/

GentiBio’s EngTregs are designed to overcome all technical hurdles of Tregs therapeutics and deliver potent and precise immune suppression fine-tuned to the individual patient needs. We Make Tregs, Simply Better.Setting and implementing strategy for early discovery projects (human product and surrogate; in vitro and in vivo).Co-inventor of GNTI-823.Project Leader responsible for delivery of 2 Treg cell therapy drug candidates into the pipeline:• Autologous product for chronic autoimmune disease indication: Primary Biliary Cholangitis (PBC).• GNTI-823: Allogeneic product for acute autoinflammatory disease indication: viral Acute Respiratory Distress Syndrome (v-ARDS).Built and led 2 Research Program Teams and the Immune Profiling Platform (IPP):• PBC and v-ARDS research teams: hired 10 biologists (4 PhDs; research associate to principal scientist) .• IPP: small platform composed of a Flow core with cell-sorting and RNAseq bioinformatic analysis capabilities (hired 2 FTEs; Scientist II and Associate Director).Active member of the Research Leadership Team (RLT).Established and led academic collaborations to broader and/or complement internal discovery and preclinical efforts.Represented Gentibio in scientific conferences and during external BD discussions.Organized Scientific Advisory Boards (SAB) and presented when necessary.

Celsius is the leader in the application of single cell genomics to drug discovery and development – with this new level of clarity, our unique approach has the transformational potential to deliver the new wave of precision medicines that could revolutionize the pharmaceutical and biotech industry. We leverage the power of single-cell RNA sequencing combined with sophisticated machine learning algorithms to analyze data of unprecedented size to discover precision medicines for complex diseases such as autoimmunity and cancer. Scientific founders include Aviv Regev, Jeffrey Bluestone, Vijay Kuchroo, Christoph Lengauer and Ramnik Xavier.As interim co-chair of the IBD Discovery group, provided drug discovery leadership support to shape IBD strategy and drug discovery portfolio.Co-led the IBD target identification subgroup, leveraging Celsius’ single cell dataset for target discovery, and prioritizing new actionable IBD targets to sustain Celsius’ discovery engine.Led the IBD target validation subgroup, ensuring a timely decision-making process with clear data-driven go/no-go points to optimize internal resources and to enable result-oriented progress to meet key milestones for program advancement.Supervised and empowered a team of direct reports including one research project leader (CEL383), guiding other program teams, mentoring more junior scientists and research project leaders across the IBD group.Identified a new IBD candidate target, leading the newly associated research project team. Engaged in several IBD external academic collaborations at various stages of development to sustain the growth of our unique single cell dataset.Represented the IBD group during BD discussions with external collaborators/partners.

Co-inventor of JTX-1811 (now GS-1811), successfully led JTX-1811 Program Team from Target inception to IND-enabling stage, leading to its Licensing by Gilead on September 1st 2020*.JTX-1811 is a therapeutic monoclonal antibody specific to human CCR8, designed to selectively deplete Tumor-infiltrating Regulatory T (TITR) cells for the treatment of human cancers.*Gilead opted for exclusive licensing of JTX-1811 program under the following terms of agreement: $85 million upfront payment, $35 million equity investment at a premium and up to an additional $685 million in future clinical, regulatory and commercial milestone payments. Jounce will also be eligible to receive royalties ranging from high single digit to mid-teens based upon worldwide sales.

Led JTX-1811 Program Team, a cross-functional discovery project team in a matrix environment from Target Identification to Drug Candidate stage, ensuring a timely decision-making process and result-oriented progress to meet key milestones enabling program success.Provided scientific guidance and strategy to articulate complex programs by defining timely clear data-driven Go/No Go decisions, priorities across functions, risk anticipation and associated mitigation plans.Supervised and mentored a team of direct reports, empowering their individual growth while promoting teamwork to reach both individual and organizational goals.

Discovering and Developing Innovative Cancer Immunotherapies at Merrimack Pharmaceuticals.Validated both ex-vivo and in-vivo the first cancer Immunotherapy Program at Merrimack: MM-401, targeting TNFR2.Led in vivo and ex vivo efforts to select mAb candidates, to identify their mode of action upon target engagement, and to strategically generate a preclinical dataset required for patent filing.

Project 1: Characterized cell population dynamic parameters conditioning Treg cell populations in vivo that informed therapeutic approaches to treat autoimmune disorders.Project 2: Developed an original model to study early events during thymic Treg cell development in vivo using a naturally diverse TCR repertoire.Project 3: Isolated and established the gene profiling of a new subset of tissue Treg cells residing in bone marrow.

Co-inventor of two innovative immunotherapies during this doctoral research experience in biotechnology company settings.Generated surrogate mAbs required for preclinical study. Designed and executed proof of principle experiments demonstrating the therapeutic efficacy of combination therapies in relevant models in mouse, and identified their mode of action in vivo.

1. Uncovered the pivotal involvement of human CD32A polymorphism in the neutralization of LPS signaling via NI-0101 therapeutic mAb.2. Identified key amino acid residues governing the Fc-mediated neutralizing activity of the mouse version of NI-0101 mAb.3. Enhanced the therapeutic activity of the final humanized version of NI-0101 mAb by grafting key residues within its Fc portion. This optimized first in class antibody, currently licensed by Edesa Biotech, renamed Paridiprubart (EB05) is in Phase 3 in ARDS indication.